Part 8-2 Cardiovascular Pharmacology Flashcards
Coagulation disorders
- Inadequate clotting: hemorrhage
- Excessive clotting: thrombogenesis
Clotting Mechanism Intrinsic System
Begins when factor XII contacts damaged vessel
Clotting Mechanism Extrinsic system
Begins when damaged vessel releases tissue factor (Thromboplastin)
Clotting Mechanism sequence
CF XII and CF VII lead to CF X
CF X turns prothrombin into Thrombin
Thrombin turns fibrinogen to Fibrin
Clot Breakdown
Tissue Plasminogen Activator turns plasminogen into plasmin
Drugs for overactive clotting
Anticoagulants
Antithrombotics
Thrombolytics
Anticoagulants
Used primarily in venous thrombosis
- Heparin
- Oral anticoagulants
Heparin
Acts by increasing effects of antithrombin III
- rapid effects
- Administered parenterally
Types of heparin
Unfractionated heparin
Low molecular weight heparins
Unfractioned heparin
- IV administration, several injections per day
- Unpredictable effects
Low molecular weight heparins
Administered sub-Q, usually 1/day
Preferentially inhibit factor Xa
More predictable, safer effect
Heparin induced thrombocytopenia
Heparins can decrease platelets
Type I HIT
Type II HIT
Type I HIT
Asymptomatic, resolves spontaneously
Type II HIT
Immune reaction…causes serious thrombosis, life/limb threatening
Oral anticoagulants
Warfarin (Coumadin)
Dicumarol
-Inhibit vitamin K function in liver
-Decreased synthesis of certain clotting factors
Oral anticoagulants administration
Oral administration
Time lag of 3-4 days
Typically used after heparin
Other Anticoagulants
Can be used as primary or if other anticoagulants aren’t tolerated
Other anticoagulant examples
Direct Thrombin inhibitors
Factor Xa Inhibitors
Antithrombotics
-Inhibit platelet activity; decrease platelet induced clot
Primary agents
-aspirin
-Newer antiplatelet drugs
Aspirin anticlotting effects
- Aspirin inhibits PG & Thrombozane (TX) biosynthesis
- Decreased TXs means less platelet induced clots
Thromboxanes (TX)
Increase platelet activity/aggregation
Aspirin
- Inhibits platelet function
- Prevents arterial thrombogenesis in MI, Ischemic stroke
- Therapeutic effects occur at very low doses
Aspirin is….
Better at preventin MI in men
Better against stroke in women
Newer antiplatelet drugs
ADP inhibitors
Glycoprotein IIb-IIa inhibitors
ADP inhibitors
Block effects of ADP on platelets
Glycoprotein IIa-IIb inhibitors
Block effects of fibrinogen, other activators on platelets
Thrombolytics
- Initiate clot breakdown by activating plasmin
- Help dissolve clots in coronary/carotid arteries
- Can restore blood flow
- Prevent/reverse damage during MI, ischemic stroke
Typical Thrombolytic agents
- Tissue plasminogen activator (activase)
- Urokinase
- Reteplase
- Tenecteplace
Thrombolytics for MI
- No agent is best for MI
- Can decrease mortality by 50% if given within 1 hr of symptoms
- May still be helpful within 3-12 hrs
Thrombolytics use in ischemic stroke
- Rule out hemorrhage first
- Activase may be preferred
- Administor within 2 hrs of symptoms
- Benefits must balance risk of intracranial hemorrhage
Anticlotting drugs rehab concerns
Risk of hemorrhage Use care when: -Dressing changes -Debridement -Aggressive manual techniques
Treatment of clotting deficiencies…hemophilia
- Clotting factor replacement
- CFs usually obtained from rDNA techniques
- Pts can also develop alloantibodies to synthetic clot factors….tx with rituximab
Hemophilia type A factor replacement
Factor VIII
Hemophilia Type B factor replacement
Factor IX
Fibrinolysis Inhibitors
Can be used in hemophilia and hyperfibrinolysis syndromes
Vitamin K supplements
- Administered to newborns or in severe vitamin K deficiency
- Can also help tx excessive warfarin
Treatment of hyperlipidemia
Statins
Fibric Acids
Others
Statin mechanism
Inhibit HMG-Co A reductase enzyme
- Decreased cholesterol biosynthesis
- Increased hepatic LDL breakdown
Statins primary effects
- Decreased LDL, VLDL cholesterol
- Decreased triglycerides
- Increased HDL
Statins other beneficial effects
Enhance vasodilation by NO Anti-inflammatory Anti-oxidant Neuroprotection? Anticancer?
Fibric Acids mechanisms
Activate nuclear receptor that effects gene controlling lipid metabolism
Fibric Acid primary effects
Decreased triglycerides
Increased VLDL breakdown
Niacin
Decreases VLDL % LDL synthesis
Decreases triglyceride levels
Ezetimibe (Zetia)
Inhibits cholesterol absorption from GI tract
Can be combined with a statin
Bile acid binding drugs
Increase GI excretion of bile acids
Decrease plasma cholesterol
Antilipid agents adverse effects
Nausea, diarrhea, bloating
Liver toxicity, pancreatitis, blood dyscrasias, arrythmias
Antilipid agents primary concern for rehab
Myalgia, Myositis, weakness, parasthesias
Statin induced myopathy
5-7% of patients taking statins
Reasons unclear
Fixed predisposing factors for statin induced myopathy
Renal/hepatic disease
Genetic factors
Advanced age
Female
Modifiable predisposing factors for statin induced myopathy
Concurrent meds
High dose
Lipophilic statin
Heavy exercise